According to the research report titled ‘Percutaneous Coronary Intervention (PCI) Devices Market Share, Size, Trends, Industry Analysis Report, By Product; By End Use; By Regions; Segment Forecast, 2020 -2027’, available with Market Study Report, global percutaneous coronary intervention (PCI) devices market is projected to grow rapidly during 2020-2027, subsequently amassing USD 11.4 billion by the year 2027.
 

Growing prevalence of cardiovascular diseases, booming geriatric population having higher susceptibility to such diseases, and increased risk factors due to lifestyle changes are contributing to global percutaneous coronary intervention (PCI) devices market expansion. Furthermore, increasing establishment of dedicated catheterization labs in high income nation is expected to propel the industry growth to new heights.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2963823/
 

Considering the end-use spectrum, catherization labs segment of global percutaneous coronary intervention (PCI) devices industry is expected showcase strong growth trends over the projected timeline. Notably, next-gen catheterization labs provide advanced services and are able to undertake several interventional therapeutic procedures such as percutaneous transluminal coronary angioplasty (PTCA), percutaneous coronary intervention (PCI), aortic valve replacements, epicardial ablations of ventricular tachycardia, and mitral valve repairs. In addition, they also perform pacemaker implantation, cardiac electrophysiological procedures, and cardiac defibrillator implantation. Thus, improved accessibility to a wide range of healthcare services at catherization labs will generate massive returns in the coming years.
 

Meanwhile, hospitals segment is slated to secure a sizeable portion of global percutaneous coronary intervention (PCI) market, attributable to increasing number of catheterization lab setups within the multi-speciality hospitals facilitated by government and private organizations. Conversion of physician's office to alternate hospital service, collaborative efforts between surgeons and manufacturers to reduce the need of general practitioner officers (GPO), and the amplification of hospital services are boosting the segmental share.
 

North America (US, Canada), Europe (UK, Italy, France, Spain, Netherlands, Austria), APAC (India, Japan, China, South Korea, Indonesia), MEA (UAE, South Africa, Israel), and Latin America (Argentina, Brazil) are the key contributors to global percutaneous coronary intervention (PCI) devices market remuneration.
 

Major industry participants include Meril Life Sciences Pvt. Ltd., Medtronic plc, Comed BV, C.R. Bard, Inc., Boston Scientific Corp., Biotronik, Biosensors International Group Ltd., B. Braun Melsungen AG, Asahi Intecc Co. Ltd., and Abbott Laboratories.